

## 2003 Grants

Investigator	Institution	Project Title	Grant Duration	Amt Granted
Laura D. Carbone, M.D. *	University of Tennessee Memphis, Tenn.	Pamidronate Inhibition of SSc Fibroblast Precursors	Two Years	\$150,000
Keith B. Elkon, M.D. *	University of Washington Seattle, Wash.	The Role of Akt and the Regulation of Apoptosis in Scleroderma Fibroblasts	Two Years	\$150,000
Barry L. Gruber, M.D. *	SUNY at Stony Brook Stony Brook, N.Y.	Mast cells activate fibroblasts in scleroderma via protease activated receptors (PAR's)	Two Years	\$150,000
Dinesh Khanna, M.D. **	University of California - Los Angeles Los Angeles, Calif.	Quality of life in scleroderma lung disease	Two Years	\$50,000
Lauren H. Kim, M.D. **	Boston Medical Center Boston, Mass.	Abnormalities of gene expression in scleroderma fibroblasts	Two Years	\$50,000
Anna Ludwicka-Bradley, PhD *	Medical University of South Carolina Charleston, S.C.	The role of thrombin and its receptor on myofibroblast differentiation in scleroderma lung fibrosis	Two Years	\$150,000
Virginia Steen, M.D. *	Georgetown University Washington, D.C.	Outcome Studies in Systemic Sclerosis using the Pittsburgh Scleroderma Databank	Two Years	\$150,000
Maria Suarez-Almazor, M.D., Ph.D. *	Baylor College of Medicine Houston, Texas	Outcome Assessment in Scleroderma	Two Years	\$149,719
Kenneth J. Warrington, M.D. *	University of Tennessee Memphis, Tenn.	Anti-fibrogenic Type I Collagen-specific Th1 Lymphocytes in Scleroderma	Two Years	\$150,000
Vladimir Yurovsky, Ph.D. *	University of Maryland at Baltimore Baltimore, M.D.	Role of TRAIL in Pulmonary Fibrosis in Scleroderma	Two Years	\$150,000
			Total Granted 2003:	\$1,299,719

\* Grants funded by the Scleroderma Foundation.

\*\* Physician Scientist Development Awards collaboratively funded by the Scleroderma Foundation and the Arthritis Foundation.